Accent Capital Management’s Nurix Therapeutics NRIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NRIX
BBA
Accent Capital Management's NRIX Position: Q3 2026 in Review
Accent Capital Management increased its Nurix Therapeutics (NRIX) stake by 34% in Q3 2026, buying an estimated $6.41K and bringing the position to 1,005 shares worth $23.8K. The position accounts for 0.01% of the portfolio, ranked #142.
Accent Capital Management first reported a position in NRIX in Q2 2025 and has held it in 6 quarters since. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.
- Accent Capital Management held 1,005 shares of Nurix Therapeutics worth $23.8K as of Q3 2026.
- Accent Capital Management bought 257 Nurix Therapeutics shares in Q3 2026, an estimated $6.41K.
- Nurix Therapeutics made up 0.01% of Accent Capital Management's portfolio in Q3 2026, its #142 holding.
- Accent Capital Management first reported a position in Nurix Therapeutics in Q2 2025 and has held it in 6 quarters since.
- 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.
Based on Accent Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.